Hormonal therapy in epithelial ovarian cancer

Gautam G. Rao, David Scott Miller

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


The ovary is an endocrine and end organ. Hormones and their receptors have been associated with ovarian cancer and may be related to its causation. Some data suggest that hormonal therapies may have an effect on ovarian cancer in palliative settings. The most well studied anticancer drugs are tamoxifen, megestrol acetate, medroxyprogesterone acetate, leuprolide acetate, anastrozole and letrozole. Presently, no hormonal therapy is approved by the US FDA for the treatment of any type of ovarian malignancy or is listed as an active agent by any of the authoritative compendia. Owing to the endocrine associations with ovarian cancer, the minimal side effects of hormonal therapy and the demonstrated activity of hormonal therapies in other endocrine organ-associated malignancies, further study of hormonal therapies for ovarian cancer is warranted.

Original languageEnglish (US)
Pages (from-to)43-47
Number of pages5
JournalExpert Review of Anticancer Therapy
Issue number1
StatePublished - 2006


  • Hormone therapy
  • Ovarian neoplasms

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Hormonal therapy in epithelial ovarian cancer'. Together they form a unique fingerprint.

Cite this